Chromadex CORP

Niagen Bioscience announced Q2 2026 results with $29.8M in net sales, launched a telehealth platform, and introduced a new therapeutic candidate for rare diseases.

Niagen Bioscience, Inc. reports results from its 2026 Annual Meeting, with all director nominees elected and auditor ratification approved.

Niagen Bioscience announced first quarter 2026 financial results, with net sales reaching $31.5 million and net income of $6.3 million.

Niagen Bioscience, Inc. announced an increase in its share repurchase program authorization from $10 million to $20 million, signaling management's confidence in its long-term value.

Niagen Bioscience, Inc. reported a robust 30% year-over-year net sales increase to $129.4 million and a 103% net income surge to $17.4 million for fiscal year 2025, alongside a positive 2026 outlook.

Niagen Bioscience, Inc. announced the sale of its analytical reference standards and services business to LGC Group in an all-cash transaction, aligning with its strategy to focus on NAD+ science.

Niagen Bioscience reported a 3% increase in net sales for Q1 2026, driven by growth in its consumer products and ingredients segments, alongside a rise in net income.

Niagen Bioscience, Inc. reported significant financial improvements for the third quarter and first nine months of 2025, driven by strong sales growth across its consumer products and ingredients segments.

Niagen Bioscience, Inc. announced a significant turnaround in its second quarter, reporting substantial net income and robust revenue growth driven by its consumer products and ingredients segments.

Niagen Bioscience announces a profitable first quarter in 2025, driven by significant growth in both consumer product and ingredient sales.

ChromaDex Corporation announced its Q3 2024 financial results, highlighted by a settlement agreement with Dartmouth College waiving $3.5 million in fees, and a 31% increase in net sales compared to Q3 2023.

ChromaDex Corporation reported a marginal net loss of $15,000 for the second quarter of 2024, despite a 12% increase in net sales compared to the same period last year.

Niagen Bioscience, Inc. reported significant revenue and net income growth in 2025, driven by strong Tru Niagen and ingredient sales, alongside strategic intellectual property and segment divestiture actions.

ChromaDex Corporation reports a profitable 2024, driven by a 19% increase in net sales, primarily from its Consumer Products and Ingredients segments.

ChromaDex Corporation amends a lease for office space, files its annual report on Form 10-K, and updates its incentive compensation recoupment policy.

Carlos Luis Lopez, SVP and General Counsel of Niagen Bioscience, Inc., acquired 2,314 shares of common stock through the company's Employee Stock Purchase Plan.

Niagen Bioscience, Inc. (NAGE) Chief Financial Officer Pamir Ozan acquired shares through the company's Employee Stock Purchase Plan.

Robert N. Fried, CEO and Director of Niagen Bioscience, Inc., reported the acquisition of 1,106 shares of common stock on June 30, 2026.

Niagen Bioscience, Inc. reports a Form 4 filing detailing the acquisition of stock options by Director Wendy Yu Wing Tak.

Director Gary Ng acquired stock options for 31,746 shares of Niagen Bioscience (NAGE) on June 24, 2026, with a vesting date of June 24, 2027.

Ann Cohen, a Director at Niagen Bioscience, Inc., acquired stock options for 31,746 shares of common stock.

Niagen Bioscience, Inc. will hold its annual shareholder meeting on June 24, 2025, to vote on director elections, auditor ratification, executive compensation, and equity incentive plan amendments.

Niagen Bioscience is asking stockholders to approve an amendment to its 2017 Equity Incentive Plan to increase the number of shares available for issuance by 4.75 million and to approve a new Employee Stock Purchase Plan.

ChromaDex Corporation will hold its annual shareholder meeting on June 20, 2024, to vote on director elections, auditor ratification, and executive compensation.

ChromaDex Corporation will hold its 2024 Annual Meeting of Stockholders on June 20, 2024, to vote on the election of directors, ratification of the independent auditor, and an advisory vote on executive compensation.

The Vanguard Group updated its beneficial ownership in Niagen Bioscience Inc., reporting a 4.11% stake as of December 31, 2025.

The Vanguard Group has filed a Schedule 13G, reporting a 5.04% beneficial ownership stake in Niagen Bioscience Inc.